All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COMET-ICE, 2021 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] COMET-ICE, 2021 1 0% 1,057 NA not evaluable deathsdetailed results BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84]
COMET-ICE, 2021 0.25 [0.01; 5.55]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05]
0.26 [0.06 ; 1.04 ] BLAZE-1 phase 3 (combo), 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 4 0% 5,073 moderate not evaluable hospitalization or deathdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18]
BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31]
BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58]
COMET-ICE, 2021 0.21 [0.09; 0.49]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68]
0.25 [0.16 ; 0.39 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020 5 0% 4,101 moderate not evaluable clinical deteriorationdetailed results COMET-ICE, 2021 0.24 [0.10; 0.56]
0.24 [0.10 ; 0.56 ] COMET-ICE, 2021 1 0% 1,057 NA not evaluable hospitalizationdetailed results COMET-ICE, 2021 0.20 [0.08; 0.48]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49]
0.18 [0.08 ; 0.43 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 0% 1,261 low not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00]
0.56 [0.31 ; 1.00 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 204 NA not evaluable viral clearance detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00]
BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38]
1.08 [0.45 ; 2.60 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 72% 470 moderate not evaluable viral clearance by day 7detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83]
BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09]
1.11 [0.63 ; 1.95 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 0% 489 moderate not evaluable emergent treatment-resistant variantsdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51]
BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47]
0.64 [0.08 ; 4.94 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 67% 497 moderate not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23]
0.25 [0.03 ; 2.23 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 311 NA not evaluable adverse eventsdetailed results COMET-ICE, 2021 0.91 [0.68; 1.22]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86]
0.73 [0.44 ; 1.20 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 71% 1,360 low not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-01 06:15 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
